Clinical Trials on Dermatitis Atopic in Chile

Total 29 results

Pontificia Universidad Catolica de Chile

Completed

Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis (VIDATOPIC)

Atopic Dermatitis

Chile
Pontificia Universidad Catolica de Chile
University of Chile; Comisión Nacional de Investigación Científica y Tecnológica

Completed

Early Origins of Allergy and Asthma (ARIES)

Asthma | Allergy | Atopic Dermatitis | Food Allergy | Allergic Sensitisation

Chile
Sanofi

Completed

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

Netherlands, Chile, United States, Canada, Czechia, Germany, Poland
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (SHORE)

Dermatitis Atopic

Japan, Chile, Canada, Argentina, United States, Turkey, China
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

Chile, United Kingdom, United States, Canada, Turkey, Israel, Korea, Republic of
Northwestern University

Completed

Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index

Psoriasis | Atopic Dermatitis

Chile, United States, Netherlands, Canada, Hong Kong, Italy
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 1)

Dermatitis Atopic

Israel, Chile, Australia, United States, France, Canada, Germany, Korea, Republic of, Taiwan, China
Sanofi

Recruiting

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (ATLANTIS)

Dermatitis Atopic

Italy, United Kingdom, Argentina, France, Chile, Czechia, Germany, Japan, Spain, China, Netherlands, Brazil, Canada, Denmark, Korea, Republic of, South Africa, Taiwan, Poland, India, Mexico
Pfizer

Completed

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Atopic Dermatitis

Spain, Taiwan, United States, Korea, Republic of, Poland, Canada, Australia, Hungary, Germany, Latvia, Finland, Chile, Bulgaria, Slovakia, Italy
Amgen

Recruiting

A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)

Atopic Dermatitis

United States, Korea, Republic of, Taiwan, Spain, Croatia, China, Greece, Belgium, Thailand, Puerto Rico, Hungary, Poland, Germany, Brazil, Italy, Japan, Canada, France, Romania, Chile
Pfizer

Active, not recruiting

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)

Dermatitis, Atopic

China, United States, Spain, Taiwan, Germany, Australia, Canada, Hungary, Korea, Republic of, Poland, Serbia, Bulgaria, Czechia, Japan, Latvia, United Kingdom, Belgium, Israel, Italy, Finland, Mexico, Romania, Slovakia, Argentina, Brazil, Chil... and more
Pfizer

Completed

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

United States, Spain, Taiwan, Germany, Canada, China, Poland, Belgium, Serbia, Brazil, Russian Federation, Israel, Latvia, Italy, Romania, Mexico, Argentina, Bulgaria, Chile, Netherlands, Slovakia
Pfizer

Completed

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)

Skin Diseases | Immune System Diseases | Hypersensitivity | Hypersensitivity, Immediate | Genetic Diseases, Inborn | Skin Diseases, Genetic | Dermatitis | Eczema | Skin Diseases, Eczematous | Dermatitis, Atopic

Spain, Taiwan, United States, Australia, Poland, Germany, Hungary, Bulgaria, Czechia, Japan, Korea, Republic of, Latvia, Canada, United Kingdom, Mexico, Chile, Slovakia, Italy
Pontificia Universidad Catolica de Chile
European Union; Agencia Nacional de Investigación y Desarrollo

Completed

Endoscopic Surveillance on a High-risk Population for Gastric Cancer in Latin America: The ECHOS Cohort Study. (ECHOS)

Gastric Cancer | Helicobacter Pylori Infection | Atrophic Gastritis | Dysplasia Stomach

Chile
University of Chile

Completed

Autologous Serum Efficacy Study in Patients With Severe Dry Eye

Dry Eye

Chile
University of Latvia
Uppsala University; Pontificia Universidad Catolica de Chile; Technion, Israel... and other collaborators

Recruiting

Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach (VOGAS)

Gastric Cancer | Gastric Dysplasia | Atrophic Gastritis | H.Pylori Infection

Brazil, Chile, Colombia, Latvia, Ukraine
Pontificia Universidad Catolica de Chile
Hospital Dr Sotero del Rio

Unknown

Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye

Dry Eye | Keratoconjunctivitis Sicca | Lacrimal Apparatus Diseases | Conjunctival Diseases | Keratitis | Corneal Diseases | Sjogren's Syndrome

Chile
Sanofi
Regeneron Pharmaceuticals

Completed

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2)

Neurodermatitis

United States, Canada, Chile, France, Hungary, Italy, Korea, Republic of, Portugal, Spain, Taiwan, United Kingdom
GlaxoSmithKline

Completed

Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug

Epilepsy, Tonic-Clonic

United States, Chile, Peru, Argentina
Eisai Inc.

Available

An Extended Access Program (EAP) for Perampanel

Lennox Gastaut Syndrome | Primary Generalized Tonic-Clonic or Partial Onset Seizures

Belgium, Chile, Estonia, Hungary, Latvia, Lithuania, Poland, Spain
GlaxoSmithKline

Completed

Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures

Epilepsy, Tonic-Clonic

United States, Germany, Korea, Republic of, Chile, India, Russian Federation, Brazil, Ukraine, Puerto Rico, Argentina, Malaysia
Newcastle-upon-Tyne Hospitals NHS Trust
Jain Foundation

Active, not recruiting

Clinical Outcome Study for Dysferlinopathy (Jain COS)

Dysferlinopathy | LGMD2B Now Classified as LGMDR2 | Miyoshi Myopathy

Korea, Republic of, Chile, Spain, United States, Denmark, France, Italy, Japan, United Kingdom
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Active, not recruiting

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Japan, China, United Kingdom, Netherlands, Spain, Norway, Russian Federation, Australia, Greece, Italy, New Zealand, Turkey, Mexico, Czechia, Canada
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Completed

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Taiwan, China, United States, United Kingdom, Netherlands, Spain, Australia, Norway, Russian Federation, Greece, Italy, Turkey, Mexico, Canada, Hong Kong, New Zealand, Ukraine
GlaxoSmithKline

Completed

A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD114044)

Muscular Dystrophies

France, Denmark, Germany, Belgium, Spain, Turkey, Korea, Republic of, Brazil, Netherlands, Italy, Chile, Japan, Canada, Hungary, Russian Federation, Czechia, Poland, Norway, Argentina, Taiwan
National Cancer Institute (NCI)
Karolinska Institutet; Vanderbilt University Medical Center, USA; New England... and other collaborators

Terminated

Helicobacter Pylori Genome Project (HpGP)

Gastric Cancer | Intestinal Metaplasia | Non-Atrophic Gastritis

Spain, Lithuania, Taiwan, Singapore, Argentina, Korea, Republic of, Sweden, Canada, United States, Peru, Puerto Rico, Mexico, Chile, Turkey, Belgium, Kenya, Malaysia, Vietnam, Colombia, Israel, Brazil, Nepal, Switzerland, Japan, Congo,... and more
PTC Therapeutics

Completed

Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) (ACT DMD)

Nervous System Diseases | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Muscular Dystrophy, Duchenne

United States, Spain, Korea, Republic of, Belgium, France, Canada, Australia, United Kingdom, Israel, Italy, Brazil, Chile, Czechia, Sweden, Switzerland, Turkey, Germany, Poland
PTC Therapeutics

Terminated

An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy

Nervous System Diseases | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Muscular Dystrophy, Duchenne

United States, Spain, Korea, Republic of, Belgium, France, Canada, Australia, United Kingdom, Israel, Italy, Germany, Brazil, Bulgaria, Chile, Czechia, Poland, Sweden, Switzerland, Turkey
GlaxoSmithKline

Terminated

Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy

Muscular Dystrophies

France, Bulgaria, Denmark, Germany, Belgium, Canada, Spain, Turkey, United Kingdom, Korea, Republic of, Brazil, Netherlands, Italy, Japan, Czech Republic, Chile, Israel, Hungary, Russian Federation, Australia, Poland, Norway, Argentina and more

Clinical Trials on Dermatitis Atopic in Chile

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations